Total Payments
$346,946
2024 Payments
$14,026
Companies
21
Transactions
336
Medicare Patients
499
Medicare Billing
$106,254
Payment Breakdown by Category
Other$242,581 (69.9%)
Consulting$66,300 (19.1%)
Travel$30,365 (8.8%)
Food & Beverage$7,688 (2.2%)
Education$11.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $184,400 | 66 | 53.1% |
| Consulting Fee | $66,300 | 31 | 19.1% |
| Travel and Lodging | $30,365 | 108 | 8.8% |
| Compensation for serving as faculty or as a speaker for a medical education program | $26,928 | 5 | 7.8% |
| Grant | $25,000 | 1 | 7.2% |
| Food and Beverage | $7,688 | 120 | 2.2% |
| Honoraria | $6,100 | 3 | 1.8% |
| Entertainment | $153.13 | 1 | 0.0% |
| Education | $11.40 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Exelixis Inc. | $134,011 | 139 | $0 (2023) |
| Eisai Inc. | $54,643 | 58 | $0 (2023) |
| Aveo Pharmaceuticals, Inc. | $52,356 | 48 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $28,584 | 26 | $0 (2021) |
| Lilly USA, LLC | $25,000 | 1 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $22,841 | 25 | $0 (2023) |
| Seagen Inc. | $8,470 | 5 | $0 (2020) |
| Janssen Biotech, Inc. | $6,660 | 9 | $0 (2021) |
| Gilead Sciences, Inc. | $5,894 | 4 | $0 (2023) |
| PFIZER INC. | $1,894 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,026 | 12 | Aveo Pharmaceuticals, Inc. ($13,743) |
| 2023 | $46,533 | 49 | Exelixis Inc. ($17,708) |
| 2022 | $42,306 | 37 | AVEO Pharmaceuticals, Inc. ($21,011) |
| 2021 | $26,387 | 31 | Exelixis Inc. ($12,624) |
| 2020 | $28,823 | 23 | Seagen Inc. ($8,470) |
| 2019 | $65,514 | 75 | Exelixis Inc. ($26,166) |
| 2018 | $73,972 | 77 | Exelixis Inc. ($30,741) |
| 2017 | $49,385 | 32 | Lilly USA, LLC ($25,000) |
All Payment Transactions
336 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/21/2024 | PFIZER INC. | INLYTA (Drug), TALZENNA, XTANDI | Food and Beverage | In-kind items and services | $3.75 | General |
| Category: ONCOLOGY | ||||||
| 06/20/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $7,245.00 | General |
| Category: Oncology | ||||||
| 06/06/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Travel and Lodging | In-kind items and services | $515.96 | General |
| Category: Oncology | ||||||
| 06/06/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Travel and Lodging | In-kind items and services | $405.58 | General |
| Category: Oncology | ||||||
| 06/06/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Travel and Lodging | In-kind items and services | $222.97 | General |
| Category: Oncology | ||||||
| 06/06/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $59.91 | General |
| Category: Oncology | ||||||
| 06/06/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Travel and Lodging | Cash or cash equivalent | $48.00 | General |
| Category: Oncology | ||||||
| 06/06/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Travel and Lodging | In-kind items and services | $12.99 | General |
| Category: Oncology | ||||||
| 06/03/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 06/02/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $143.49 | General |
| Category: Oncology | ||||||
| 05/07/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $3,220.00 | General |
| Category: Oncology | ||||||
| 05/07/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $2,013.00 | General |
| Category: Oncology | ||||||
| 12/05/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Travel and Lodging | Cash or cash equivalent | $130.72 | General |
| Category: Oncology | ||||||
| 12/05/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | Cash or cash equivalent | $50.03 | General |
| Category: Oncology | ||||||
| 12/05/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Travel and Lodging | Cash or cash equivalent | $44.00 | General |
| Category: Oncology | ||||||
| 12/05/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Travel and Lodging | Cash or cash equivalent | $18.61 | General |
| Category: Oncology | ||||||
| 12/05/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Travel and Lodging | Cash or cash equivalent | $13.10 | General |
| Category: Oncology | ||||||
| 11/29/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $7,225.00 | General |
| Category: Oncology | ||||||
| 11/29/2023 | Progenics Pharmaceuticals, Inc. | PYLARIFY (Drug) | Food and Beverage | In-kind items and services | $24.94 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 11/17/2023 | Exelixis Inc. | CABOMETYX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,980.00 | General |
| Category: Oncology | ||||||
| 11/13/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Travel and Lodging | In-kind items and services | $283.96 | General |
| Category: Oncology | ||||||
| 11/13/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Travel and Lodging | In-kind items and services | $195.93 | General |
| Category: Oncology | ||||||
| 11/13/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $62.01 | General |
| Category: Oncology | ||||||
| 10/31/2023 | Exelixis Inc. | CABOMETYX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: Oncology | ||||||
| 10/18/2023 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $326.99 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 126 | 221 | $116,466 | $23,502 |
| 2022 | 4 | 129 | 271 | $134,963 | $29,563 |
| 2021 | 6 | 155 | 327 | $159,752 | $35,749 |
| 2020 | 3 | 89 | 204 | $94,977 | $17,440 |
Total Patients
499
Total Services
1,023
Medicare Billing
$106,254
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 59 | 133 | $78,601 | $15,411 | 19.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 51 | 72 | $25,337 | $5,600 | 22.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 16 | 16 | $12,528 | $2,491 | 19.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 62 | 148 | $84,805 | $18,372 | 21.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 17 | 55 | $22,022 | $4,805 | 21.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 38 | 56 | $19,228 | $4,457 | 23.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 12 | 12 | $8,908 | $1,928 | 21.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 55 | 144 | $80,731 | $17,105 | 21.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 39 | 80 | $26,053 | $6,868 | 26.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 17 | 56 | $21,764 | $4,982 | 22.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 21 | 21 | $18,190 | $3,627 | 19.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 12 | 12 | $8,736 | $1,947 | 22.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 11 | 14 | $4,278 | $1,221 | 28.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 53 | 152 | $78,941 | $14,014 | 17.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 25 | 37 | $11,599 | $2,388 | 20.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 11 | 15 | $4,437 | $1,038 | 23.4% |
About Randy Sweis
Randy Sweis is a Hematology & Oncology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/25/2010. The National Provider Identifier (NPI) number assigned to this provider is 1093034498.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Randy Sweis has received a total of $346,946 in payments from pharmaceutical and medical device companies, with $14,026 received in 2024. These payments were reported across 336 transactions from 21 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($184,400).
As a Medicare-enrolled provider, Sweis has provided services to 499 Medicare beneficiaries, totaling 1,023 services with total Medicare billing of $106,254. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Chicago, IL
- Active Since 05/25/2010
- Last Updated 10/24/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1093034498
Products in Payments
- Cabometyx (Drug) $103,665
- Lenvima (Drug) $54,643
- FOTIVDA (Drug) $52,356
- CABOMETYX (Drug) $30,332
- OPDIVO (Biological) $27,574
- IMFINZI (Drug) $10,384
- LYNPARZA (Drug) $9,129
- PADCEV (Biological) $8,748
- Balversa (Drug) $5,145
- Trodelvy (Drug) $3,170
- BAVENCIO (Drug) $1,836
- PADCEV (Drug) $1,665
- BALVERSA (Drug) $1,515
- Nerlynx (Drug) $1,125
- KIMMTRAK (Drug) $838.74
- Nubeqa (Drug) $39.73
- KEYTRUDA (Biological) $31.95
- PYLARIFY (Drug) $24.94
- INC280 (Drug) $12.90
- SUTENT (Drug) $11.40
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Chicago
Michael Bishop
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Young Kwang Chae, Md, Mph, Mba, MD, MPH, MBA
Hematology & Oncology — Payments: $682,642
Hematology & Oncology $682,642
Irfan Mirza, Md, MD
Hematology & Oncology — Payments: $644,273
Hematology & Oncology $644,273
Everett Vokes
Hematology & Oncology — Payments: $449,910
Hematology & Oncology $449,910
Peter Riedell
Hematology & Oncology — Payments: $374,919
Hematology & Oncology $374,919
Rita Nanda
Hematology & Oncology — Payments: $374,678
Hematology & Oncology $374,678